Pharmaceutical Executive-12-21-2005

Pharmaceutical Executive

Doctors and academics are praising Pfizer’s plan to allow the Cleveland Clinic to compare Celebrex with two NSAIDs. Is the company courageous, or is it taking to big of a risk?

A recent spate of false positive results using OraSure’s test has officials and company representatives scrambling to figure out what is causing these anomalies and how to stop them from impacting testing rates.

Agency hopes to inform healthcare providers and patients about comparisons of treatments for gastroesophagealreflux disease.